Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC von Camidge, D. Ross, Doebele, Robert C., Kerr, Keith M.

Volltext

Molecular Pathways: ROS1 Fusion Proteins in Cancer von DAVIES, Kurtis D, DOEBELE, Robert C

Volltext

TRKing down an old oncogene in a new era of targeted therapy von Vaishnavi, Aria, Le, Anh T, Doebele, Robert C

Volltext

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials von Drilon, Alexander, Siena, Salvatore, Dziadziuszko, Rafal, Barlesi, Fabrice, Krebs, Matthew G, Shaw, Alice T, de Braud, Filippo, Rolfo, Christian, Ahn, Myung-Ju, Wolf, Jürgen, Seto, Takashi, Cho, Byoung Chul, Patel, Manish R, Chiu, Chao-Hua, John, Thomas, Goto, Koichi, Karapetis, Christos S, Arkenau, Hendrick-Tobias, Kim, Sang-We, Ohe, Yuichiro, Li, Yu-Chung, Chae, Young K, Chung, Christine H, Otterson, Gregory A, Murakami, Haruyasu, Lin, Chia-Chi, Tan, Daniel S W, Prenen, Hans, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R, Doebele, Robert C

Volltext

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study von Gainor, Justin F, Curigliano, Giuseppe, Kim, Dong-Wan, Lee, Dae Ho, Besse, Benjamin, Baik, Christina S, Doebele, Robert C, Cassier, Philippe A, Lopes, Gilberto, Tan, Daniel S W, Garralda, Elena, Paz-Ares, Luis G, Cho, Byoung Chul, Gadgeel, Shirish M, Thomas, Michael, Liu, Stephen V, Taylor, Matthew H, Mansfield, Aaron S, Zhu, Viola W, Clifford, Corinne, Zhang, Hui, Palmer, Michael, Green, Jennifer, Turner, Christopher D, Subbiah, Vivek

Volltext

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer von Robichaux, Jacqulyne P., Elamin, Yasir Y., Tan, Zhi, Carter, Brett W., Zhang, Shuxing, Liu, Shengwu, Li, Shuai, Chen, Ting, Poteete, Alissa, Estrada-Bernal, Adriana, Le, Anh T., Truini, Anna, Nilsson, Monique B., Sun, Huiying, Roarty, Emily, Goldberg, Sarah B., Brahmer, Julie R., Altan, Mehmet, Lu, Charles, Papadimitrakopoulou, Vassiliki, Politi, Katerina, Doebele, Robert C., Wong, Kwok-Kin, Heymach, John V.

Volltext

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples von Davies, Kurtis D., Le, Anh T., Sheren, Jamie, Nijmeh, Hala, Gowan, Katherine, Jones, Kenneth L., Varella-Garcia, Marileila, Aisner, Dara L., Doebele, Robert C.

Volltext

Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Pati... von Gan, Gregory N., MD, PhD, Weickhardt, Andrew J., MBBS, DMedSc, Scheier, Benjamin, MD, Doebele, Robert C., MD, PhD, Gaspar, Laurie E., MD, MBA, Kavanagh, Brian D., MD, MPH, Camidge, D. Ross, MD, PhD

Volltext

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer von McCoach, Caroline E, Le, Anh T, Gowan, Katherine, Jones, Kenneth, Schubert, Laura, Doak, Andrea, Estrada-Bernal, Adriana, Davies, Kurtis D, Merrick, Daniel T, Bunn, Jr, Paul A, Purcell, W Tom, Dziadziuszko, Rafal, Varella-Garcia, Marileila, Aisner, Dara L, Camidge, D Ross, Doebele, Robert C

Volltext

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases von Hilberg, Frank, Tontsch-Grunt, Ulrike, Baum, Anke, Le, Anh T, Doebele, Robert C, Lieb, Simone, Gianni, Davide, Voss, Tilman, Garin-Chesa, Pilar, Haslinger, Christian, Kraut, Norbert

Volltext

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer von Davies, Kurtis D, Mahale, Sakshi, Astling, David P, Aisner, Dara L, Le, Anh T, Hinz, Trista K, Vaishnavi, Aria, Bunn, Jr, Paul A, Heasley, Lynn E, Tan, Aik-Choon, Camidge, D Ross, Varella-Garcia, Marileila, Doebele, Robert C

Volltext

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer von McCoach, Caroline E, Blakely, Collin M, Banks, Kimberly C, Levy, Benjamin, Chue, Ben M, Raymond, Victoria M, Le, Anh T, Lee, Christine E, Diaz, Joseph, Waqar, Saiama N, Purcell, William T, Aisner, Dara L, Davies, Kurtis D, Lanman, Richard B, Shaw, Alice T, Doebele, Robert C

Volltext

Identifying and Targeting ROS1 Gene Fusions in Non―Small Cell Lung Cancer von DAVIES, Kurtis D, LE, Anh T, ALLOISIO, Marco, SANTORO, Armando, ROSS CAMIDGE, D, VARELLA-GARCIA, Marileila, DOEBELE, Robert C, THEODORO, Mariana F, SKOKAN, Margaret C, AISNER, Dara L, BERGE, Eamon M, TERRACCIANO, Luigi M, CAPPUZZO, Federico, INCARBONE, Matteo, RONCALLI, Massimo

Volltext

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer von Weickhardt, Andrew J., Scheier, Benjamin, Burke, Joseph Malachy, Gan, Gregory, Lu, Xian, Bunn, Paul A., Aisner, Dara L., Gaspar, Laurie E., Kavanagh, Brian D., Doebele, Robert C., Camidge, D. Ross

Volltext

Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer von Rusthoven, Chad G, Doebele, Robert C

Volltext

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes von Estrada-Bernal, Adriana, Le, Anh T, Doak, Andrea E, Tirunagaru, Vijaya G, Silva, Shevan, Bull, Matthew R, Smaill, Jeff B, Patterson, Adam V, Kim, Chul, Liu, Stephen V, Doebele, Robert C

Volltext

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations von Rich, Thereasa A, Reckamp, Karen L, Chae, Young Kwang, Doebele, Robert C, Iams, Wade T, Oh, Michael, Raymond, Victoria M, Lanman, Richard B, Riess, Jonathan W, Stinchcombe, Thomas E, Subbiah, Vivek, Trevarthen, David R, Fairclough, Stephen, Yen, Jennifer, Gautschi, Oliver

Volltext

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression von Ware, Kathryn E, Marshall, Marianne E, Heasley, Lydia R, Marek, Lindsay, Hinz, Trista K, Hercule, Paula, Helfrich, Barbara A, Doebele, Robert C, Heasley, Lynn E

Volltext

Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor von Berge, Eamon M, Doebele, Robert C

Volltext

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment von ROSS CAMIDGE, D, KONO, Scott A, FLACCO, Antonella, TAN, Aik-Choon, DOEBELE, Robert C, QING ZHOU, CRINO, Lucio, FRANKLIN, Wilbur A, VARELLA-GARCIA, Marileila

Volltext